IDEAYA Biosciences Announces IDE892, a Potential Best-in-Class MTA-Cooperative PRMT5 Inhibitor, Initiates Part 2 Monotherapy Expansion in the Phase 1/2 Study in MTAP-Deleted Pancreatic and Lung Cancers

Phase 2IDE892Positive

AI Analysis

Summary

IDEAYA Biosciences announced IDE892, a PRMT5 inhibitor, and initiated Part 2 monotherapy expansion in a Phase 1/2 study for MTAP-deleted pancreatic and lung cancers.

Clinical Trial Data

Phase

1/2

Importance:6/10

Sentiment:

0.50

PRMT5 inhibitorMTAP-deleted cancersmonotherapyPhase 1/2pancreatic cancerlung cancer

Related Companies

$IDYA

Read the original article

Published by yahoo_finance on July 27, 2026 10:00 AM

Read Original